Member Info for K-mac

I think this time next year, providing positive phase 3 results and potentially partnerships, and no buy out probably sitting £15-£20 a share.

All the LTHs here know what can happen here in a single day. When this bounces, it’s going to bounce big. Just hold for now it’ll come good.

Kinaset?

This is one of those shares that you’ll look at in 10 years time and think “imagine if I’d taken a punt on that”. So the punt has been punted.

Would bloody love for it to be sitting at 85 quid!

Data won’t be lacking for long. “ IFN-ß-1a could also be useful in viral diseases like hepatitis and may reduce mortality and cut short the period of illness in COVID-19. Trials on its inhalable form, SNG001, are going on in patients with chronic obstructive pulmonary disease (COPD) or asthma, with very encouraging results. IFN-ß-1b might also be useful in early disease onset, since it promotes endothelial barrier integrity and increases adenosine levels, but firm data is lacking.”

Not sure if this includes the MAP agreement with SNG or not.

https://www.marketscreener.com/quote/stock/CLINIGEN-GROUP-PLC-11560493/news/Clinigen-expands-partnership-with-Accord-Healthcare-in-Clinical-Services-into-France-31856018/

Cheers, Kmac

Agreed, one day this’ll take a mighty bounce back up and it’ll soon come clear what’s been going on.

Caravan, this is phase II.

Sorry to hear that CW. All the best to your folks.

Going by the deadline 18th Nov - 8:30am, does anyone else think we will see some TR1s this week or early next?

Long shot I know, but this clinical trial for the vaccine has exactly 20 uk locations. Seems to have had a few updates in the last few days, but nothing to do with Inf-beta. Just a thought.

https://clinicaltrials.gov/ct2/show/NCT04400838

We don't know if the 'pilot phase' of the home trial has been concluded or not, but my assumption is that the original 100 slots was surpassed and has moved onto the next phase. See the comparison below where the it states "Once each of the Pilot phases are complete, a Pivotal phase will be conducted. It is estimated that the size of each of the Pivotal phases (hospital and home) will be around 100 to 300 patients per arm. The actual number will be determined after the data review at the end of each of the Pilot phases"

Obviously again just speculation.

https://www.clinicaltrials.gov/ct2/history/NCT04385095?A=1&B=2&C=Side-by-Side#StudyPageTop

Dishing out the big finds as per Pmjh! That’s awesome.

I think the COVID trials will begin in the next week personally. I’m not sure how ethical/legal it would be for them to outline a strict use for investors £80million to only go and use it for something else. All is on track and will become clear tomorrow.

Totally agree woodstock, I’ll happily hold this for a few years it thats where its going with COPD. And then there’s every other potential respiratory disorder you can think of to trial! Onwards and upwards.

Some big delayed buys once again! Tasty

I'm unsure of this find, personally I think we will see a new phase 3 stand alone trial for inhaled interferon, rather than all the convoluted changes that would come with adapting the ACTT-3 trial to inhaled interferon, adding a hell of a lot more locations etc. I'd prefer it anyway... does not mean I am right, just a thought. If the ACTT trial was adapted in this way would patients still be given doses of remdesivir alongside interferon, or what is the current situ? Lot's of news to come regardless. I for one cannot wait to find out.

I work for schlumberger, this happens allll the bloody time, it’s hilarious ??. Luckily i found the ignore thread button.

Leornard licht below 3%